CNCR:NSD-Loncar Cancer Immunotherapy ETF (USD)

ETF | Health |

Last Closing

USD 14.95

Change

-0.12 (-0.80)%

Market Cap

USD 0.01B

Volume

1.18K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ("ADRs") with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund"s total assets will be invested in the component securities of the index.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

+0.70 (+0.48%)

USD 7.60B
IBB iShares Biotechnology ETF

+0.70 (+0.48%)

USD 7.60B
PPH VanEck Pharmaceutical ETF

+0.19 (+0.20%)

USD 0.72B
PPH VanEck Pharmaceutical ETF

+0.19 (+0.20%)

USD 0.72B
BBH VanEck Biotech ETF

+0.79 (+0.45%)

USD 0.45B
BBH VanEck Biotech ETF

+0.79 (+0.45%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

+0.53 (+1.16%)

USD 0.20B
PSCH Invesco S&P SmallCap Health Ca..

+0.53 (+1.16%)

USD 0.20B
PTH Invesco DWA Healthcare Momentu..

+0.55 (+1.20%)

USD 0.15B
PTH Invesco DWA Healthcare Momentu..

+0.55 (+1.20%)

USD 0.15B

ETFs Containing CNCR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.99% 69% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.99% 69% C- 66% D+
Trailing 12 Months  
Capital Gain 42.11% 94% A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.11% 94% A 81% B-
Trailing 5 Years  
Capital Gain -17.54% 6% D- 37% F
Dividend Return 11.81% 93% A 46% F
Total Return -5.73% 19% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain -6.39% N/A N/A 30% F
Dividend Return -4.57% N/A N/A 30% F
Total Return 1.82% N/A N/A 42% F
Risk Return Profile  
Volatility (Standard Deviation) 31.53% N/A N/A 59% D-
Risk Adjusted Return -14.51% N/A N/A 31% F
Market Capitalization 0.01B 6% D- 13% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.